Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Bullish - Simplified Treatment / Based on Info Gathered

<< Previous

Bullboard Posts

Next >>

Comment by Arbourmarkon Mar 16, 2021 10:12am

108 Views

Post# 32806801

RE:Bullish - Simplified Treatment / Based on Info Gathered

Very promiyand sounds like very few negative reactions observed on first 45 patients and the rewards outweigh the risks.

I wonder once study is completed if Emergency Use Authorization applied for.

Todays news kind of mirrors the Turkish request to add 20 more patients, in both cases people outside of Arch making requests. This is extremely positive. Then you add the grant they received from Federal Government plus how fast Health Canada approved today's changes.

I simply Canada believe where this share price is. We have a small float, high insider ownership, no outstanding warrants.

Good luck to all!

<< Previous

Bullboard Posts

Next >>

Mastering options Greeks: Essential knowledge for informed trading